▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

BostonGene to Present AI-Powered Solutions Advancing Patient-Centric Drug Development at The Festival of Genomics & Biodata Boston 2025

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced its participation in The Festival of Genomics & Biodata Boston, taking place June 24 - 25 at the Bo...

Business Wire

BostonGene’s VP of R&D Mike Goldberg PhD to Lead Session on Transforming Drug Development with AI and Precision Analytics

WALTHAM, Mass.: BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced its participation in The Festival of Genomics & Biodata Boston, taking place June 24 - 25 at the Boston Convention & Exhibition Center in Boston, MA.

The Festival of Genomics & Biodata Boston is the premier life sciences event in the U.S., bringing together thousands of global genomics and biodata professionals for two days of cutting-edge research, technology showcases and networking. The event spotlights the latest advances in genomic science and their real-world applications in healthcare and beyond.

Mike Goldberg, PhD, BostonGene’s Vice President of R&D, will host a session titled “Redefining Precision Oncology with an End-to-End AI Platform for Drug Development.” The session will focus on how BostonGene’s AI-driven technologies are accelerating innovation across the drug development process and enabling more personalized, data-driven approaches to cancer care.

Session details:

  • Date & time: Tuesday, June 24 | 4:40 PM – 5:10 PM
  • Location: AI in Discovery Stage

To schedule a meeting during the event, please contact Hannah Oman at events@bostongene.com. For more details about the event, visit The Festival of Genomics & Biodata website.

About BostonGene Corporation

BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit www.BostonGene.com.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!